Abstract
The poor outcomes in retinoblastoma necessitate new treatments. Salinomycin is an attractive candidate, and has demonstrated selective anti-cancer properties in different cancer types. This work addressed the efficacy of salinomycin in retinoblastoma models and probe the associated mechanisms. Cellular functional assays were conducted to determine the effects salinomycin in vitro. Xenograft retinoblastoma mouse model was established to investigate the efficacy of salinomycin in vivo. Biochemical assays were conducted to analyze the mechanism of salinomycin’s action focusing on mitochondrial functions, energy reduction-related signaling pathways. Salinomycin has positive effects towards retinoblastoma cells regardless of heterogeneity through suppressing growth and inducing apoptosis. Salinomycin also specifically inhibits cells displaying stemness and highly invasive phenotypes. Using retinoblastoma xenograft mouse model, we show that salinomycin at non-toxic dose effectively inhibits growth and induces apoptosis. Mechanistic studies show that salinomycin inhibits mitochondrial respiration via specifically suppressing complex I and II activities, reduces mitochondrial membrane potential and decreases energy reduction, followed by induction of oxidative stress and damage, AMPK activation and mTOR inhibition. Our study highlights that adding salinomycin to the existing treatment armamentarium for retinoblastoma is beneficial.
Similar content being viewed by others
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
References
Bejjani A, Choi MR, Cassidy L, Collins DW, O’Brien JM, Murray T, Ksander BR, Seigel GM (2012) RB116: an RB1+ retinoblastoma cell line expressing primitive markers. Mol vis 18:2805–2813
Busch M, Philippeit C, Weise A, Dunker N (2015) Re-characterization of established human retinoblastoma cell lines. Histochem Cell Biol 143:325–338
Cassoux N, Lumbroso L, Levy-Gabriel C, Aerts I, Doz F, Desjardins L (2017) Retinoblastoma: update on current management. Asia Pac J Ophthalmol (Philaos) 6:290–295
Chandel NS, Schumacker PT (1999) Cells depleted of mitochondrial DNA (rho0) yield insight into physiological mechanisms. FEBS Lett 454:173–176
Cork GK, Thompson J, Slawson C (2018) Real talk: the inter-play between the mTOR, AMPK, and hexosamine biosynthetic pathways in cell signaling. Front Endocrinol (lausanne) 9:522
De Luca A, Fiorillo M, Peiris-Pages M, Ozsvari B, Smith DL, Sanchez-Alvarez R, Martinez-Outschoorn UE, Cappello AR, Pezzi V, Lisanti MP, Sotgia F (2015) Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-like cancer cells. Oncotarget 6:14777–14795
Dewangan J, Tandon D, Srivastava S, Verma AK, Yapuri A, Rath SK (2017) Novel combination of salinomycin and resveratrol synergistically enhances the anti-proliferative and pro-apoptotic effects on human breast cancer cells. Apoptosis 22:1246–1259
Gao CF, Xie Q, Su YL, Koeman J, Khoo SK, Gustafson M, Knudsen BS, Hay R, Shinomiya N, Vande Woude GF (2005) Proliferation and invasion: plasticity in tumor cells. Proc Natl Acad Sci USA 102:10528–10533
Gehrke T, Hackenberg S, Polat B, Wohlleben G, Hagen R, Kleinsasser N, Scherzad A (2018) Combination of salinomycin and radiation effectively eliminates head and neck squamous cell carcinoma cells in vitro. Oncol Rep 39:1991–1998
Gruber M, Handle F, Culig Z (2020) The stem cell inhibitor salinomycin decreases colony formation potential and tumor-initiating population in docetaxel-sensitive and docetaxel-resistant prostate cancer cells. Prostate 80:267–273
Harada Y, Ishii I, Hatake K, Kasahara T (2012) Pyrvinium pamoate inhibits proliferation of myeloma/erythroleukemia cells by suppressing mitochondrial respiratory complex I and STAT3. Cancer Lett 319:83–88
Hashiguchi K, Zhang-Akiyama QM (2009) Establishment of human cell lines lacking mitochondrial DNA. Methods Mol Biol 554:383–391
Hochmair M, Rath B, Klameth L, Ulsperger E, Weinlinger C, Fazekas A, Plangger A, Zeillinger R, Hamilton G (2020) Effects of salinomycin and niclosamide on small cell lung cancer and small cell lung cancer circulating tumor cell lines. Investig New Drugs 38:946–955
Hu H, Deng F, Liu Y, Chen M, Zhang X, Sun X, Dong Z, Liu X, Ge J (2012) Characterization and retinal neuron differentiation of WERI-Rb1 cancer stem cells. Mol vis 18:2388–2397
Ke F, Yu J, Chen W, Si X, Li X, Yang F, Liao Y, Zuo Z (2018) The anti-malarial atovaquone selectively increases chemosensitivity in retinoblastoma via mitochondrial dysfunction-dependent oxidative damage and Akt/AMPK/mTOR inhibition. Biochem Biophys Res Commun 504:374–379
Kivela T (2009) The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death. Br J Ophthalmol 93:1129–1131
Klose J, Trefz S, Wagner T, Steffen L, Preissendorfer Charrier A, Radhakrishnan P, Volz C, Schmidt T, Ulrich A, Dieter SM, Ball C, Glimm H, Schneider M (2019) Salinomycin: anti-tumor activity in a pre-clinical colorectal cancer model. PLoS ONE 14:e0211916
Ko JC, Zheng HY, Chen WC, Peng YS, Wu CH, Wei CL, Chen JC, Lin YW (2016) Salinomycin enhances cisplatin-induced cytotoxicity in human lung cancer cells via down-regulation of AKT-dependent thymidylate synthase expression. Biochem Pharmacol 122:90–98
Lagadinou ED, Sach A, Callahan K, Rossi RM, Neering SJ, Minhajuddin M, Ashton JM, Pei S, Grose V, O’Dwyer KM, Liesveld JL, Brookes PS, Becker MW, Jordan CT (2013) BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 12:329–341
Lee HG, Shin SJ, Chung HW, Kwon SH, Cha SD, Lee JE, Cho CH (2017) Salinomycin reduces stemness and induces apoptosis on human ovarian cancer stem cell. J Gynecol Oncol 28:e14
Luengo A, Gui DY, Vander Heiden MG (2017) Targeting metabolism for cancer therapy. Cell Chem Biol 24:1161–1180
Mahmood T, Yang PC (2012) Western blot: technique, theory, and trouble shooting. N Am J Med Sci 4:429–434
Mai TT, Hamai A, Hienzsch A, Caneque T, Muller S, Wicinski J, Cabaud O, Leroy C, David A, Acevedo V, Ryo A, Ginestier C, Birnbaum D, Charafe-Jauffret E, Codogno P, Mehrpour M, Rodriguez R (2017) Salinomycin kills cancer stem cells by sequestering iron in lysosomes. Nat Chem 9:1025–1033
Manago A, Leanza L, Carraretto L, Sassi N, Grancara S, Quintana-Cabrera R, Trimarco V, Toninello A, Scorrano L, Trentin L, Semenzato G, Gulbins E, Zoratti M, Szabo I (2015) Early effects of the antineoplastic agent salinomycin on mitochondrial function. Cell Death Dis 6:e1930
Manmuan S, Sakunrangsit N, Ketchart W (2017) Salinomycin overcomes acquired tamoxifen resistance through AIB1 and inhibits cancer cell invasion in endocrine resistant breast cancer. Clin Exp Pharmacol Physiol 44:1042–1052
Markowska A, Kaysiewicz J, Markowska J, Huczynski A (2019) Doxycycline, salinomycin, monensin and ivermectin repositioned as cancer drugs. Bioorg Med Chem Lett 29:1549–1554
Mitani M, Yamanishi T, Miyazaki Y, Otake N (1976) Salinomycin effects on mitochondrial ion translocation and respiration. Antimicrob Agents Chemother 9:655–660
Skeberdyte A, Sarapiniene I, Aleksander-Krasko J, Stankevicius V, Suziedelis K, Jarmalaite S (2018) Dichloroacetate and salinomycin exert a synergistic cytotoxic effect in colorectal cancer cell lines. Sci Rep 8:17744
Skrtic M, Sriskanthadevan S, Jhas B, Gebbia M, Wang X, Wang Z, Hurren R, Jitkova Y, Gronda M, Maclean N, Lai CK, Eberhard Y, Bartoszko J, Spagnuolo P, Rutledge AC, Datti A, Ketela T, Moffat J, Robinson BH, Cameron JH, Wrana J, Eaves CJ, Minden MD, Wang JC, Dick JE, Humphries K, Nislow C, Giaever G, Schimmer AD (2011) Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell 20:674–688
Stenfelt S, Blixt MKE, All-Ericsson C, Hallbook F, Boije H (2017) Heterogeneity in retinoblastoma: a tale of molecules and models. Clin Transl Med 6:42
Sun J, Luo Q, Liu L, Yang X, Zhu S, Song G (2017) Salinomycin attenuates liver cancer stem cell motility by enhancing cell stiffness and increasing F-actin formation via the FAK-ERK1/2 signalling pathway. Toxicology 384:1–10
Theriault BL, Dimaras H, Gallie BL, Corson TW (2014) The genomic landscape of retinoblastoma: a review. Clin Exp Ophthalmol 42:33–52
Tung CL, Chen JC, Wu CH, Peng YS, Chen WC, Zheng HY, Jian YJ, Wei CL, Cheng YT, Lin YW (2017) Salinomycin acts through reducing AKT-dependent thymidylate synthase expression to enhance erlotinib-induced cytotoxicity in human lung cancer cells. Exp Cell Res 357:59–66
Tyagi M, Patro BS (2019) Salinomycin reduces growth, proliferation and metastasis of cisplatin resistant breast cancer cells via NF-kB deregulation. Toxicol in Vitro 60:125–133
Winter U, Ganiewich D, Ottaviani D, Zugbi S, Aschero R, Sendoya JM, Cafferata EG, Mena M, Sgroi M, Sampor C, Lubieniecki F, Fandino A, Abba MC, Doz F, Podhjacer O, Carcaboso AM, Letouze E, Radvanyi F, Chantada GL, Llera AS, Schaiquevich P (2020) Genomic and transcriptomic tumor heterogeneity in bilateral retinoblastoma. JAMA Ophthalmol 138:569–574
Yu M, Li R, Zhang J (2016) Repositioning of antibiotic levofloxacin as a mitochondrial biogenesis inhibitor to target breast cancer. Biochem Biophys Res Commun 471:639–645
Zheng J (2012) Energy metabolism of cancer: glycolysis versus oxidative phosphorylation (review). Oncol Lett 4:1151–1157
Zhou J, Sun M, Jin S, Fan L, Zhu W, Sui X, Cao L, Yang C, Han C (2019) Combined using of paclitaxel and salinomycin active targeting nanostructured lipid carriers against non-small cell lung cancer and cancer stem cells. Drug Deliv 26:281–289
Acknowledgements
This work was supported by Nature Science Foundation of Hubei Province (2016-A06).
Author information
Authors and Affiliations
Contributions
JL and YM designed the experiments; JL performed the experiments and wrote the manuscript; All authors interpreted the data, supervised the project and revised the manuscript.
Corresponding author
Ethics declarations
Research involving human participants and/or animals
This work was approved by the institutional review board of Tongji Medical College, Huazhong University of Science and Technology on 26 August 2018 (Approval No. 2018-C05). This study was conducted in accordance with the Declaration of Helsinki.
Conflict of interest
All authors declare no conflict of interest.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Li, J., Min, Y. Pre-clinical evidence that salinomycin is active against retinoblastoma via inducing mitochondrial dysfunction, oxidative damage and AMPK activation. J Bioenerg Biomembr 53, 513–523 (2021). https://doi.org/10.1007/s10863-021-09915-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10863-021-09915-2